The authors reply

New England Journal of Medicine

Volumn 371, Issue 25, 2014, Pages 2434-

  Bel, Elisabeth H ^a   Ortega, Hector G ^b   Pavord, Ian D ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; MEPOLIZUMAB; PLACEBO; PREDNISONE;

ADRENAL INSUFFICIENCY; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE 5 SCORE; CATARACT; CONTROLLED CLINICAL TRIAL (TOPIC); COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOCUMENTATION; DOSE RESPONSE; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; LETTER; MAINTENANCE THERAPY; MUSCLE WEAKNESS; PATIENT COMPLIANCE; PRESCRIPTION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEASONAL VARIATION; SPINE FRACTURE; TREATMENT DURATION;

EID: 84919348857     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1412892     Document Type: Letter

References (5)

1. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001;56:279-84.
2. Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 2011;33:1413-32.
3. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009;103:975-94.
4. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012;129:1229-35.
5. Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J 2014;44:239-41.